Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Trans-Tasman collaboration leads to new rotavirus vaccine

Trans-Tasman collaboration leads to new rotavirus vaccine


Thursday 4 September 2014

A new rotavirus vaccine that has the potential to save over half a million lives worldwide each year has reached a pivotal milestone after clinical trials results found the vaccine provided a strong immune response in over 90 per cent of babies that received a course of the vaccine.

Rotavirus is the most common cause of severe diarrhoea among infants and young children and results in the death of over half a million children under five years of age worldwide each year, mainly in developing countries.

The clinical trial, which was done in collaboration between the University of Otago and the Murdoch Childrens Research Institute at the University of Melbourne, involved 95 babies at Dunedin Hospital receiving a course of three doses of the vaccine, with the first dose given within the first days of birth.

The breakthrough results will be presented at the 11th International Rotavirus Symposium currently underway in New Delhi, India.

Lead researcher, Professor Julie Bines of Murdoch Childrens, the University of Melbourne and The Royal Children’s Hospital said the results provide confidence that this vaccine will be very effective in preventing severe rotavirus gastroenteritis in very young babies.

“These results are a major step forward for the development of the vaccine as it is the first time a rotavirus vaccine has been given to newborns. Not only have we shown that this novel vaccine is well tolerated in newborns but it produces a strong immune response in a newborn, suggestive of promoting early protection from severe gastroenteritis,” she says.

“The advantage of this vaccine over the currently available vaccines is the birth dose which is the earliest opportunity to provide protection to babies from severe rotavirus gastroenteritis. This world-first approach has enormous potential to reduce disease and dying in the most vulnerable children around the world.”

The ‘RV3’ Rotavirus Vaccine candidate has been developed from a unique strain of rotavirus that was found naturally in healthy asymptomatic newborn babies, who were then protected from severe rotavirus diarrhea in the first two years of life.

University of Otago Senior Clinical Lecturer in Women and Children’s Health Dr Pam Jackson says the clinical trial in Dunedin went very well, and she thanks families for their participation, and also the Health Research Council (HRC) of New Zealand, which funded the study.

“Without their willingness to help this would have been difficult to assess, and we are delighted that this vaccine has been shown to be an effective way to prevent this disease.”

Newborn babies and infants in Dunedin were given three doses of the oral vaccine, called RV3-BB, or a placebo to ascertain the level of immunity to rotavirus generated by the vaccine. The vaccine is derived from a harmless strain of rotavirus found in newborn babies. In New Zealand, rotavirus is responsible for 1500 hospital admissions of children under five years of age each year.

Although babies in Australia have had the benefit of rotavirus vaccines the new vaccine has a number of advantages, such as the ability to administer earlier and prevent disease in very young babies that are currently not protected.

The research and development of the ‘RV3’ vaccine is being led and conducted by academic institutions rather than the pharmaceutical industry with the intention to partner with developing country manufacturers so that the vaccine will ultimately be affordable for developing countries, where they are needed most.

The vaccine is the culmination of over four decades of research in Australia by the Murdoch Childrens Research Institute, The Royal Children's Hospital Melbourne and the University of Melbourne, following the discovery of rotavirus by a team of staff led by Professor Ruth Bishop in 1973.

Clinical trials are also underway in Indonesia. It is hoped the vaccine will be available for widespread use in 2016.
ends

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

BusinessDesk: APN's NZME Sees Future In Paywalls, Growth In Digital Sales

APN News & Media has touted a single newsroom concept for its NZME unit in New Zealand, similar to what Germany's Die Welt uses, saying an 'integrated sales proposition' is helping it win market share, including ... More>>

Labour Party: Global Milk Prices Now Lowest In 6 Years

The latest fall in the global dairy price has brought it to the lowest level in six years and shows there must be meaningful action in tomorrow’s Budget to diversify the economy, says Labour’s Finance spokesperson Grant Robertson. “Dairy prices ... More>>

BusinessDesk: NZ Inflation Expectations Creep Higher In June Survey

May 19 (BusinessDesk) - New Zealand businesses lifted their expectations for inflation over the next two years, sapping any immediate pressure on the Reserve Bank to cut interest rates, and prompting the kiwi dollar to jump higher. More>>

BusinessDesk: Lower Fuel Costs Drive Down NZ Producer Input, Output Prices

May 19 - Producer input and output prices fell in the first quarter, mainly reflecting lower fuel costs and weakness in prices of meat and dairy products. More>>

Media: Fairfax Media NZ Announces Senior Editorial Team

Fairfax Media New Zealand has today confirmed its new editorial leadership team, as part of a transformation of its newsrooms aimed at enhancing local and national journalism across digital and print. More>>

Science: Flavonoids Reduce Cold And Cough Risk

Flavonoids reduce cold and cough risk Research from the University of Auckland shows eating flavonoids – found in green tea, apples, blueberries, cocoa, red wine and onions – can significantly reduce the risk of catching colds and coughs. The research, ... More>>


BusinessDesk: RBNZ House Alert Speech The Catalyst For Government Action

Prime Minister John Key all but conceded that pressure from the Reserve Bank of New Zealand for concerted action on rampant Auckland house prices was one of the main catalysts for the government's weekend announcements about tightly ... More>>

BusinessDesk: How To Fall Foul Of The New Housing Tax Rules: Tips From IRD

Just because you rented out your investment property doesn't absolve you from paying tax, says the Inland Revenue Department in a summary of commonly made mistakes by non-professional property investors when it comes to their tax liability.More>>

Legal: Superdiversity Law, Policy And Business Stocktake Announced

Mai Chen, Managing Partner at Chen Palmer New Zealand Public and Employment Law Specialists and Adjunct Professor of Law at the University of Auckland, today announced the establishment ... More>>

Housing: More House Price Gains Expected

House price expectations remain high, with a net 56% of respondents expecting house prices will increase. Fears of higher interest rates are fading, consistent with the RBNZ’s signals this year. Affordability and a lack of houses for ... More>>

TDDA: State-Of-The-Art Drug Testing Laboratory To Open In Auckland

World leading drug testing agencies, The Drug Detection Agency (TDDA) and Omega Laboratories, open New Zealand laboratory More>>

Network: Bigpipe Launches Ultra-Fast Broadband Into Wellington

Bigpipe Launches Ultra-Fast Broadband into Wellington Naked broadband provider Bigpipe has extended its national reach, announcing today, the launch of its unlimited UFB offering into Wellington. The Spark Venture business is giving Wellingtonians the ... More>>

Get More From Scoop

 
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news